This study investigates the use of an investigational immunotherapy for patients with unresectable pancreatic cancer. It focuses on individuals who have not shown disease progression after initial chemotherapy treatment.
This study evaluates the safety and effectiveness of the immunotherapy as a maintenance treatment. The purpose of this study is to understand how well the treatment works and how safe it is for patients.
- Who can participate: Adults aged 18 and older with pancreatic cancer that is unresectable or metastatic may participate. Participants must have stable disease or partial response after recent chemotherapy.
- Study details: Participants will receive an investigational immunotherapy. Some may receive a placebo, an inactive substance that looks like the investigational medicine but does not contain any medicine.